5-HT2C Serotonin Receptor

Subscribe to Selected New Research on 5-HT2C Serotonin Receptor

144 relevant articles (7 outcomes, 20 trials/studies) found for this Bio-Agent

Description: A serotonin receptor subtype found primarily in the CENTRAL NERVOUS SYSTEM and the CHOROID PLEXUS. This receptor subtype is believed to mediate the anorectic action of SEROTONIN, while selective antagonists of the 5-HT2C receptor appear to induce ANXIETY. Several isoforms of this receptor subtype exist, due to adenine deaminase editing of the receptor mRNA.

Also Known As:

Receptor, Serotonin, 5-HT2C; 5-HT(2C) Receptor; 5-HT2C Receptor; 5-Hydroxytryptamine Type 2C Receptor; 5-Hydroxytryptamine Type 2C Receptors; Receptor, 5-Hydroxytryptamine Type 2C; 2C Receptor, Serotonin; 5 HT2C Receptor; 5 Hydroxytryptamine Type 2C Receptor; 5 Hydroxytryptamine Type 2C Receptors; Receptor, 5 Hydroxytryptamine Type 2C; Receptor, 5-HT2C; Receptor, Serotonin 2C; Serotonin 2C Receptor

Relationship Network

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins

Proteins: 56522

Membrane Proteins: 4214

Cell Surface Receptors: 633

G-Protein-Coupled Receptors: 403

Serotonin Receptors: 406

5-HT2 Serotonin Receptors: 28

5-HT2C Serotonin Receptor: 144

Neurotransmitter Receptors: 266

Biogenic Amine Receptors: 3

Serotonin Receptors: 406

5-HT2 Serotonin Receptors: 28

5-HT2C Serotonin Receptor: 144

Biogenic Amine Receptors: 3

Serotonin Receptors: 406

5-HT2 Serotonin Receptors: 28

5-HT2C Serotonin Receptor: 144

Experts

1.	Reynolds, Gavin P: 6 articles (06/2008 - 08/2002)
2.	Langhans, Wolfgang: 3 articles (03/2007 - 01/2003)
3.	Iwamoto, Kazuya: 2 articles (04/2008 - 08/2003)
4.	Kato, Tadafumi: 2 articles (04/2008 - 08/2003)
5.	Gallardo, Charlemagne S: 2 articles (01/2008 - 03/2005)
6.	Tsai, James H: 2 articles (01/2008 - 03/2005)
7.	Webb, Robert R: 2 articles (01/2008 - 03/2005)
8.	Chen, Rita R: 2 articles (01/2008 - 03/2005)
9.	Smith, Brian M: 2 articles (01/2008 - 03/2005)
10.	Sengupta, Dipanjan: 2 articles (01/2008 - 03/2005)

Related Diseases

1.	Weight Loss (Weight Reduction) 06/01/2002 - "Association between a polymorphism of the 5-HT2C receptor and weight loss in teenage girls." 04/01/2004 - "A 5-HT2C receptor promoter polymorphism (HTR2C - 759C/T) is associated with obesity in women, and with resistance to weight loss in heterozygotes." 07/01/2000 - "In light of the sustained drug effect on body weight, the data suggest that weight loss by 5-HT(2C) receptor stimulation may be only partly dependent on changes in food consumption and that 5-HT(2C) receptor agonists may have effects on thermogenesis" 01/01/2003 - "Indirect evidence stems from recent observations that the clinically effective anorectic agent d-fenfluramine exerts its hypophagic and weight-loss effects via 5-HT(2C) receptor activation" 01/01/2007 - "Weight loss in the obese has also been produced by treatment with both the serotonin precursor 5-hydroxytryptophan and the preferential 5-HT2C receptor agonist mCPP.A new generation of 5-HT2C receptor selective agonists have been developed and at least one, lorcaserin (APD356), is currently undergoing clinical trials" Get all the results and reference details, order at left...
2.	Obsessive-Compulsive Disorder (Disorder, Obsessive-Compulsive) 07/01/2008 - "The improved performance in reversal learning observed following 5-HT(2C) receptor antagonism suggests these receptors may offer the potential for therapeutic advances in a number of neuropsychiatric disorders where cognitive deficits are a feature, including obsessive-compulsive disorder." 03/01/2006 - "5-HT2c receptor activation induces grooming behaviour in rats: possible correlations with obsessive-compulsive disorder." 08/01/1998 - "These results suggest that 5-HT2C receptor agonism is associated with therapeutic potential in obsessive compulsive disorder and depression." 06/01/2007 - "OBJECTIVE: The present studies were conducted to evaluate the effects of the novel 5-HT2C receptor agonist WAY-163909 in animal models of antidepressant activity (forced swim test (FST), resident-intruder, olfactory bulbectomy (BULB)), in a schedule-induced polydipsia (SIP) model of obsessive-compulsive disorder and in a model for evaluating sexual dysfunction" 11/01/2006 - "The 5-HT(2C) receptor subtype has been implicated in a wide variety of conditions including obesity, anxiety, depression, obsessive compulsive disorder, schizophrenia, migraine and erectile dysfunction and as a consequence has received considerable attention as a target for drug discovery" Get all the results and reference details, order at left...
3.	Syndrome 10/01/1998 - "Selective 5-HT(2C) receptor ligands may offer innovative and improved therapeutic opportunities for the biological treatment of specific aspects of psychiatric syndromes." 12/01/1998 - "Previous studies have shown that mice bearing a targeted disruption of the 5-HT2C receptor gene exhibit an epilepsy syndrome associated with sporadic spontaneous seizures that occasionally result in death" 03/01/2005 - "We studied the dopamine D3 receptor ser9gly, the dopamine D2 receptor Taq IA and the 5-HT2C receptor promoter -759C/T polymorphisms in 117 patients who had symptoms assessed by Positive and Negative Syndrome Scale (PANSS) on admission and following 10-week antipsychotic treatment, primarily with risperidone or chlorpromazine" Get all the results and reference details, order at left...
4.	Anxiety Disorders (Anxiety Disorder) 12/01/2003 - "This caused much interest in the development of antagonists at the 5-HT2C receptor for the treatment of anxiety disorders" 12/01/2003 - "Therapeutic potential of 5-HT2C receptor antagonists in the treatment of anxiety disorders." 08/01/2004 - "Thus, the clinical efficacy of fluvoxamine on anxiety disorders might involve the normalization of the 5-HT2C receptor function." 02/01/2001 - "Alternative approaches to the treatment of anxiety include the following: (i) antidepressants such as the selective serotonin reuptake inhibitors (SSRIs), which are active in treating most anxiety disorders, including GAD; (ii) metabotropic glutamate (mGluR2) receptor agonists, which negatively modulate glutamate neurotransmission, and CRF antagonists, which have been proposed to exhibit anxiolytic properties; (iii) 5-HT1A receptor agonists which have demonstrated anxiolytic effects in clinical studies, although preclinical studies have reported weak or variable effects; (iv) 5-HT moduline antagonists, as well as 5-HT2C receptor antagonists, which may have anxiolytic properties; and, finally, (v) other approaches which are under investigation, including CCK2 antagonists." Get all the results and reference details, order at left...
5.	Obesity 10/01/2000 - "The 5-HT2C receptor may prove to be a useful target in the development of clinically effective drugs for the treatment of obesity." 08/01/2008 - "Substituted 2,3,4,4a-tetrahydropyrazino[2,1-c][1,4]benzoxazin-5-(1H)-ones were synthesized and evaluated as 5-HT(2C) receptor agonists for the possible treatment of obesity" 05/01/2008 - "These data demonstrate lorcaserin to be a potent, selective, and efficacious agonist of the 5-HT(2C) receptor, with potential for the treatment of obesity." 02/01/2008 - "CONCLUSIONS: Lower frequency of -759T allele of the 5- HT2C receptor gene was associated with type 2 diabetes but not with obesity in male and female Caucasians" 02/01/2008 - "Our aim was to determine the possible association of the -759C/T polymorphism of the 5-HT2C receptor gene with type 2 diabetes and obesity in male and female individuals Caucasian origin" Get all the results and reference details, order at left...
60 Diseases and 144 more articles analyzed in the Research Interface, order at left...

Related Drugs and Biologics

1.	Fenfluramine
2.	Fluvoxamine (Luvox)
3.	Ligands
4.	Serotonin (5 Hydroxytryptamine)
5.	1-(3-chlorophenyl)piperazine
6.	SB 206553
7.	5-HT1A Serotonin Receptor
8.	5-Hydroxytryptophan (5 Hydroxytryptophan)
9.	Cocaine (Cocaine HCl)
10.	Antidepressive Agents (Antidepressants)
81 Drugs and Important Bio-Agents and 76 more articles analyzed in the Research Interface, order at left...

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>